Pfizer Inc. Reports Below Forecast, Shares Falls After Earnings
Ticker: PFE
Current Price: $24.59
-0.26%
on November 04, 2025
Pfizer Inc. (Ticker: PFE) has recently experienced a modest decline in its stock price, currently trading at $24.59, down 0.26% for the day. The pharmaceutical giant has faced various market challenges, including fluctuating demand for its COVID-19 vaccines and treatments, impacting investor sentiment. Despite these headwinds, Pfizer remains a key player in the healthcare sector, with a robust pipeline of new therapies and ongoing research initiatives. As the market navigates uncertainties, Pfizer’s strategic focus on innovation and growth may position it for potential recovery and long-term success.
📰 Recent Developments
Recent news highlights include a surge in inflation rates, prompting speculation about potential interest rate hikes by central banks. This development could lead to increased borrowing costs, affecting consumer spending and business investments. Additionally, geopolitical tensions in Eastern Europe have raised concerns about energy supply disruptions, further exacerbating inflationary pressures. In the tech sector, earnings reports revealed mixed results, with some companies exceeding expectations while others fell short, leading to volatility in stock prices. Overall, these factors could create a cautious market environment, as investors weigh the implications of rising inflation and geopolitical uncertainties on economic growth and corporate earnings in the coming months.
💰 Earnings History
| Earnings Date | EPS Estimate | Reported EPS | Surprise(%) | Event Type |
|---|---|---|---|---|
| 2025-04-29 | 0.66 | 0.92 | 38.83 | Earnings |
| 2025-04-25 | nan | nan | nan | Meeting |
| 2025-02-04 | 0.47 | 0.63 | 33.84 | Earnings |
| 2024-10-29 | 0.62 | 1.06 | 71.39 | Earnings |
| 2024-07-30 | 0.46 | 0.6 | 31.58 | Earnings |
| 2024-05-01 | 0.52 | 0.82 | 56.58 | Earnings |
| 2024-01-30 | -0.22 | 0.1 | 145.84 | Earnings |
| 2023-10-31 | -0.34 | -0.17 | 49.39 | Earnings |
The earnings data reveals a strong upward trend in earnings per share (EPS) over recent quarters, with several notable surprises. In the most recent report on April 29, 2025, the company reported an EPS of 0.92, significantly exceeding the estimate of 0.66, resulting in a surprise of 38.83%. This follows a pattern of positive earnings surprises, with the February 2025 report showing an EPS of 0.63 against an estimate of 0.47, marking a 33.84% surprise. The strongest performance occurred in October 2024, where EPS reached 1.06 compared to an estimate of 0.62, yielding a remarkable 71.39% surprise. Despite a challenging period in late 2023, where the EPS was -0.17, the consistent upward revisions and positive surprises indicate a robust recovery and improved operational performance, suggesting growing investor confidence moving forward.
💵 Dividend History
| Date | Dividend |
|---|---|
| 2025-07-25 | 0.43 |
| 2025-05-09 | 0.43 |
| 2025-01-24 | 0.43 |
| 2024-11-08 | 0.42 |
| 2024-07-26 | 0.42 |
| 2024-05-09 | 0.42 |
| 2024-01-25 | 0.42 |
| 2023-11-09 | 0.41 |
The dividend data reflects a stable upward trend in payouts over the past few years. Starting from $0.41 in November 2023, dividends have gradually increased to $0.43 by mid-2025. This consistent growth indicates a positive outlook, suggesting that the company is not only committed to returning value to its shareholders but also demonstrates financial health and profitability.
The incremental increases, from $0.41 to $0.43, highlight a cautious yet optimistic approach to dividend distribution. The consistent timing of dividends every quarter also reinforces the company’s commitment to maintaining a reliable income stream for investors.
Such stability in dividends can attract long-term investors looking for steady returns, especially in uncertain economic times. Overall, these trends suggest a company focused on sustainable growth and shareholder value, which is crucial for maintaining investor confidence and market competitiveness.
⭐ Analyst Ratings
| Date | Status | Outer | Rating | Price |
|---|---|---|---|---|
| 2025-04-22 00:00:00 | Initiated | Cantor Fitzgerald | Neutral | $24 |
| 2024-12-10 00:00:00 | Resumed | BofA Securities | Neutral | $29 |
| 2024-11-15 00:00:00 | Initiated | Wolfe Research | Underperform | $25 |
| 2024-10-25 00:00:00 | Resumed | Citigroup | Neutral | $30 |
Recent rating changes reflect a cautious sentiment among analysts regarding the stock’s performance. Cantor Fitzgerald initiated coverage with a “Neutral” rating at a price target of $24, suggesting a balanced outlook but indicating potential concerns about upside. Similarly, BofA Securities resumed coverage with a “Neutral” rating at $29, aligning with a wait-and-see approach as market conditions evolve.
In contrast, Wolfe Research’s initiation of an “Underperform” rating at $25 signals a more pessimistic view, suggesting that the stock may face challenges that could hinder its growth. Citigroup’s resumption of coverage with a “Neutral” rating at $30 indicates a recognition of stability amidst the varying assessments.
Overall, the trend suggests a lack of strong conviction among analysts, highlighting uncertainty in the stock’s trajectory, which may be influenced by broader market dynamics and company-specific factors. Investors should consider these insights when evaluating potential investment opportunities.
Disclaimer
The content on MarketsFN.com is provided for educational and informational purposes only. It does not constitute financial advice, investment recommendations, or trading guidance. All investments involve risks, and past performance does not guarantee future results. You are solely responsible for your investment decisions and should conduct independent research and consult a qualified financial advisor before acting. MarketsFN.com and its authors are not liable for any losses or damages arising from your use of this information.
